Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

Clinical trial NCT03259529 · COMPLETED

Trial details

NCT number

NCT03259529

Sponsor

St. Petersburg State Pavlov Medical University

Status

COMPLETED

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2017-03-27

Primary completion

2020-01-27

Enrollment

30

View on ClinicalTrials.gov